Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11155988 | 0.87 | GLA (0.50) | BCHEACHECYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL28614654 | 0.86 | GLA (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL31072452 | 0.81 | PRMT3 (0.49) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL30020019 | 0.81 | L3MBTL1 (0.49) | BCHEACHECYP1A2MAPK1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL9349126 | 0.81 | PRMT3 (0.45) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8608071 | 0.79 | HSD17B10 (0.44) | BCHEACHELTA4HITGB3ITGA2B | |
| SCHEMBL11410375 | 0.78 | ALOX15 (0.55) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL21472144 | 0.78 | GLA (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18930342 | 0.78 | HSD11B1 (0.54) | BCHEACHESMN1; SMN2LTA4HITGB3 | |
| SCHEMBL12617222 | 0.77 | ITGB3 (0.52) | GNAI3GNAO1GNAI1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092160-A2 | BIFUNCTIONAL PROTEASES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2022036229-A2 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021081515-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252396-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PRMT3 2797/4885CARM1 3739/4885PRMT6 3473/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PRMT3 2797/4885CARM1 3739/4885PRMT6 3473/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | PRMT3 3790/4885CARM1 4339/4885PRMT6 4165/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | PRMT3 2797/4885CARM1 3739/4885PRMT6 3473/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PRMT3 2797/4885CARM1 3739/4885PRMT6 3473/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | PRMT3 3790/4885CARM1 4339/4885PRMT6 4165/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | PRMT3 3862/4885CARM1 4821/4885PRMT6 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.